Ultragenyx Pharmaceutical Inc. Price & Performance (RARE)

Barclays PLC has acquired over 126,000 shares of Ultragenyx Pharmaceutical, reflecting heightened institutional interest. Meanwhile, analysts maintain a bullish stance, with most rating the stock a buy and price targets averaging near $92.79, suggesting significant upside from current levels. The company’s market cap stands at $3.51 billion.12

Recent forecasts for rare disease therapies anticipate U.S. sales reaching $109 million this year, accelerating to $428 million in 2026. These projections underscore the sector’s momentum, driven by FDA designations such as Breakthrough Therapy and Priority Review, and the pursuit of accelerated approvals for new treatments.3

Ultragenyx has granted nearly 37,000 restricted stock units to 21 new hires as part of its ongoing talent expansion. The move comes as the company advances key clinical programs, including setrusumab for osteogenesis imperfecta, with pivotal trial updates expected later this year. Pre-commercial activities are also underway.42